trial
as of 2026-07-01An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
NCTId NCT06315283
at a glance
Phase 1 · Completed
Enrollment 153 (actual)
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.
Primary completion 2025-08-14
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
153 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Crossover
Masking
None
Start
2024-03-20
Primary completion
2025-08-14
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Drugs
Indications
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.Lead Sponsor
Investigators
1
Teva Medical Expert, MDStudy Director
Sites
9 total
Los Alamitos, United StatesTorrance, United StatesHollywood, United StatesAtlanta, United StatesDecatur, United StatesMarlton, United StatesZagreb, CroatiaZamora, SpainSurrey, United Kingdom
Facts & assertions
4 sourced
Enrollment
153
Phase
PHASE1
Primary Completion Date
2025-08-14
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
indication
indication
indication
investigator
person